Membrane Phospholipid Alterations In Alzheimer's Disease: Deficiency of Ethanolamine Plasmalogens

The ethanolamine plasmalogens are decreased whereas serine glycerophospholipids are significantly increased in plasma membrane phospholipid in affected regions of brain in Alzheimer's disease. This may be due to stimulation of Ca2+-independent plasmalogen-selective phospholipase A2, which was recently discovered in brain. This phospholipase A2 differs from other Ca2+-independent phospholipases A2 in response to ATP and various inhibitors. It may be responsible for excess release of arachidonic acid and accumulation of prostaglandins and lipid peroxides in AD. Accumulation of the above lipid metabolites due to abnormal receptor function and signal transduction may contribute to neurodegeneration in AD.

[1]  S. Hazen,et al.  ATP-dependent regulation of rabbit myocardial cytosolic calcium-independent phospholipase A2. , 1991, The Journal of biological chemistry.

[2]  P. Crino,et al.  Involvement of free radicals in dementia of the Alzheimer type: A hypothesis , 1990, Neurobiology of Aging.

[3]  L. Horrocks,et al.  Involvement of glutamate receptors, lipases, and phospholipases in long‐term potentiation and neurodegeneration , 1994, Journal of neuroscience research.

[4]  P. Jenner.  Oxidative damage in neurodegenerative disease , 1994, The Lancet.

[5]  L. Horrocks,et al.  Breakdown of membrane phospholipids in Alzheimer disease. Involvement of excitatory amino acid receptors. , 1995, Molecular and chemical neuropathology.

[6]  J. Growdon,et al.  Alterations of Phospholipid Metabolites in Postmortem Brain from Patients with Alzheimer's Disease a , 1991, Annals of the New York Academy of Sciences.

[7]  L. Horrocks,et al.  Plasmalogens, phospholipases A2 and signal transduction , 1995, Brain Research Reviews.

[8]  S. Rapoport,et al.  Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain , 1995, Brain Research.

[9]  K. Kristensson,et al.  Lipid Compositions of Different Regions of the Human Brain During Aging , 1990, Journal of neurochemistry.

[10]  D. Selkoe,et al.  Cytosolic Phospholipase A2(cPLA2) Immunoreactivity Is Elevated in Alzheimer's Disease Brain , 1996, Neurobiology of Disease.

[11]  K. Kosaka,et al.  The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients , 1989, Journal of Neurology.

[12]  L. Horrocks,et al.  Neurochemical aspects of Alzheimer's disease: Involvement of membrane phospholipids , 1988, Metabolic Brain Disease.

[13]  E. Masliah,et al.  Quantitative synaptic alterations in the human neocortex during normal aging , 1993, Neurology.

[14]  D. Selkoe.  The molecular pathology of Alzheimer's disease , 1991, Neuron.

[15]  A. Novelli,et al.  Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced , 1988, Brain Research.

[16]  E. Dennis,et al.  Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization. , 1994, The Journal of biological chemistry.

[17]  L. Horrocks,et al.  Neural membrane phospholipids in alzheimer disease , 1995, Neurochemical Research.

[18]  B. Halliwell.  Free radicals and antioxidants: a personal view. , 2009, Nutrition reviews.

[19]  L. Horrocks,et al.  Effects of glycosaminoglycans and glycosphingolipids on cytosolic phospholipases A2 from bovine brain. , 1994, The Biochemical journal.

[20]  W. Ying.  Deleterious network hypothesis of Alzheimer's disease. , 1996, Medical hypotheses.

[21]  E. Dennis,et al.  Mammalian calcium-independent phospholipase A2. , 1995, Biochimica et biophysica acta.

[22]  C. Jeandel,et al.  Lipid peroxidation and free radical scavengers in Alzheimer's disease. , 1989, Gerontology.

[23]  J. Rogers,et al.  Neuroimmune Mechanisms in Alzheimer Disease Pathogenesis , 1994, Alzheimer disease and associated disorders.

[24]  R. Katzman.,et al.  Advances in Alzheimer's disease , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  Lin Chen,et al.  Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. , 1994, The International journal of neuroscience.

[26]  L. Horrocks,et al.  Elevated Activities of Lipases and Lysophospholipase in Alzheimer's Disease , 1990 .

[27]  L. Ang,et al.  Autopsy Samples of Alzheimer's Cortex Show Increased Peroxidation In Vitro , 1990, Journal of neurochemistry.

[28]  J. Pettegrew,et al.  31P Nuclear Magnetic Resonance Study of the Brain in Alzheimer's Disease , 1988, Journal of neuropathology and experimental neurology.

[29]  L. Horrocks,et al.  Brain phospholipases and their role in signal transduction. , 1992, Advances in experimental medicine and biology.

[30]  M. Olson,et al.  Platelet-activating factor: receptors and signal transduction. , 1993, The Biochemical journal.

[31]  R. Gross,et al.  Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion. , 1994, Biochemistry.

[32]  L. Horrocks,et al.  Pathway for hydrolysis of plasmalogens in brain. , 1978, Advances in experimental medicine and biology.

[33]  E. Rojas,et al.  β-amyloid Ca2+-channel hypothesis for neuronal death in Alzheimer Disease , 1994, Molecular and Cellular Biochemistry.

[34]  J. D. Clark,et al.  Purification of a 110-kilodalton cytosolic phospholipase A2 from the human monocytic cell line U937. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Hawthorne,et al.  Reduced Phosphoinositide Concentrations in Anterior Temporal Cortex of Alzheimer‐Diseased Brains , 1987, Journal of neurochemistry.

[36]  C. Raetz,et al.  A possible role for plasmalogens in protecting animal cells against photosensitized killing. , 1988, The Journal of biological chemistry.

[37]  L. Horrocks,et al.  Identification and Purification of Calcium‐Independent Phospholipase A2 from Bovine Brain Cytosol , 1992, Journal of neurochemistry.

[38]  J. Pettegrew.  Molecular Insights into Alzheimer's Disease , 1989, Annals of the New York Academy of Sciences.

[39]  J. Growdon,et al.  Evidence for a membrane defect in Alzheimer disease brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Atack,et al.  Evidence for a membrane lipid defect in Alzheimer disease. , 1993, Molecular and chemical neuropathology.

[41]  S. Hazen,et al.  Purification and characterization of canine myocardial cytosolic phospholipase A2. A calcium-independent phospholipase with absolute f1-2 regiospecificity for diradyl glycerophospholipids. , 1990, The Journal of biological chemistry.

[42]  J. Pettegrew,et al.  Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia , 1995, Neurobiology of Aging.

[43]  S. Hazen,et al.  Human myocardial cytosolic Ca(2+)-independent phospholipase A2 is modulated by ATP. Concordant ATP-induced alterations in enzyme kinetics and mechanism-based inhibition. , 1991, The Biochemical journal.

[44]  L. Horrocks,et al.  Plasmalogenase is elevated in early demyelinating lesions. , 1978, Advances in experimental medicine and biology.

[45]  L. Horrocks,et al.  Effects of sialic acid and sialoglycoconjugates on cytosolic phospholipases A2 from bovine brain. , 1994, Biochemical and biophysical research communications.